Download PDF
Thromb Haemost 2009; 101(03): 591-593
DOI: 10.1160/TH08-09-0578
Letters to the Editor
Schattauer GmbH

Pharmacogenetics of acenocoumarol: CYP2C9 *2 and VKORC1 c.-1639G>A, 497C>G, 1173C>T, and 3730G>A variants influence drug dose in anticoagulated patients

Zoraida Verde
1   Universidad Europea de Madrid, Madrid, Spain
,
Catalina Santiago
1   Universidad Europea de Madrid, Madrid, Spain
,
Beatriz Valle
2   Fundación Tejerina, Madrid, Spain
,
Ana Fernández-Santander
1   Universidad Europea de Madrid, Madrid, Spain
,
Fernando Bandrés
2   Fundación Tejerina, Madrid, Spain
,
Elpidio Calvo
2   Fundación Tejerina, Madrid, Spain
,
Jonatan R. Ruiz
3   Hospital Clínico de San Carlos, Madrid, Spain
,
Alejandro Lucía
1   Universidad Europea de Madrid, Madrid, Spain
,
Félix Gómez Gallego
1   Universidad Europea de Madrid, Madrid, Spain
› Author Affiliations
Further Information

Publication History

Received: 05 September 2008

Accepted after major revision: 11 February 2008

Publication Date:
24 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Hirsh J, Dalen JE, Anderson DR. et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1998; 114: 4455-4695.
    PubMedGoogle Scholar
  • 2 Gage BF, Eby CS. Pharmacogenetics and anticoagulant therapy. J Thromb Thrombolysis 2003; 16: 73-78.
    CrossrefPubMedGoogle Scholar
  • 3 Oldenburg J, Bevans CG, Freging A. et al. Current pharmacogenetic developments in oral anticoagulation therapy: The influence of variant VKORC1 and CYP2CP alleles. Thromb Haemost 2007; 98: 570-578.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Thijssen HH, Flinois JP, Beaune PH. Cytochrome P4502C9 is the principal catalystic of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab Dispos 2000; 28: 1284-1290.
    PubMedGoogle Scholar
  • 5 Hermida J, Zarza J, Alberca I. et al. Differential effects of 2C9*3 and 2CP*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol. Blood 2002; 99: 4237-4239.
    CrossrefPubMedGoogle Scholar
  • 6 Tassies D, Freire C, Pijoan J. et al. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation. Haematologica 2002; 87: 1185-1191.
    PubMedGoogle Scholar
  • 7 Rieder MJ, Reiner AP, Gage BF. et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-2293.
    CrossrefPubMedGoogle Scholar
  • 8 D’Andrea G, D’Ambrosio RL, Di Perna P. et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105: 645-649.
    CrossrefPubMedGoogle Scholar
  • 9 Geisen C, Watzka M, Sittinger K. et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost 2005; 94: 773-779.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Yuan HY, Chen JJ, Lee MT. et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 2005; 14: 1745-1751.
    CrossrefPubMedGoogle Scholar
  • 11 Montes M, Ruiz de Gaona E, Martínez-González MA. et al. The c.-1639G>A polymorphism of the VKCORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients. Br J Haematol 2006; 133: 183-187.
    CrossrefPubMedGoogle Scholar
  • 12 Bodin L, Verstuyft C, Tregouet DA. et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005; 106: 135-140.
    CrossrefPubMedGoogle Scholar
  • 13 Reitsma PH, van der Heijden JF, Groot AP. et al. A C1173T dimorphism in the VKCOR1 gene determined coumarin sensitivity and bleeding risk. PloS Med 2005; 2: e312.
    CrossrefPubMedGoogle Scholar
  • 14 Schwarz UI, Ritchie MD, Bradford Y. et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358: 999-1008.
    CrossrefPubMedGoogle Scholar
  • 15 Meckley LM, Wittkowsky AK, Rieder MJ. et al. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Thromb Haemost 2008; 100: 229-239.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 2005; 7: 97-104.
    CrossrefPubMedGoogle Scholar
  • 17 Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-coagulation in patients on long-term treatment. Blood 2000; 96: 1816-1819.
    PubMedGoogle Scholar
  • 18 Yin T, Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 –Rationale and perspectives. Thromb Res 2007; 120: 1-10.
    CrossrefPubMedGoogle Scholar
  • 19 Schalekamp T, Brasse BP, Roijers JF. et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther 2006; 80: 13-22.
    CrossrefPubMedGoogle Scholar
  • 20 Spreafico M, Lodigiani C, van LY, Pizzotti D. et al. Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy. Pharmacogenomics 2008; 9: 1237-1250.
    CrossrefPubMedGoogle Scholar